Determination of Andarine (S-4), a Selective Androgen Receptor Modulator, and Ibutamoren (MK-677), a Nonpeptide Growth Hormone Secretagogue, in Urine by Ultra-High Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection
- 686 Downloads
A procedure for the determination of a selective androgen receptor modulator andarine (S-4) and a nonpeptide growth hormone secretagogue ibutamoren (MK-677) in urine has been developed including sample preparation by the “dilute-and-shoot” procedure, separation of analytes by ultra-high performance liquid chromatography in the gradient elution mode, and mass-spectrometric detection with heated electrospray ionization. The limits of detection are in the range of 0.5–2.5 ng/mL, the calibration curves are linear in the range of 2.5–250 ng/mL for andarine and 5–250 ng/mL for ibutamoren. The proposed procedure was used for the analysis of urine samples obtained from volunteers after a single administration of these drugs containing 15 mg of active substances.
Keywordsultra-high performance liquid chromatography tandem mass spectrometry selective androgen receptor modulators nonpeptide growth hormone secretagogue andarine ibutamoren “dilute-and-shoot” doping control
Unable to display preview. Download preview PDF.
- 3.World Anti-Doping Agency, The World Anti-Doping Code, The 2008 Prohibited List, International Standard, 2008. www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2008_EN.pdf. Accessed May 7, 2017.Google Scholar
- 14.Sobolevsky, T., Prasolov, I., and Rodchenkov, G., Recent Adv. Doping Anal., 2013, p.182.Google Scholar
- 15.Identification criteria for qualitative assays incorporating column chromatography and mass spectrometry, WADA Technical Document TD2015IDCR, 2015. www.wada-ama.org/sites/default/files/resources/files/td2015idcr_-_eng.pdf. Accessed May 7, 2017.Google Scholar
- 20.FDA Guidance for Industry: Bioanalytical Method Validation, Rockville: US Department of Health and Human Services, Food and Drug Administration (FDA), 2013. https://doi.org/www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf. Accessed May 7, 2017.